What is the Purpose of this Study?

The purpose of this study is to find new ways to treat lymphomas that have either come back after treatment or have stopped responding to treatment in patients who have aggressive B-cell non-Hodgkin lymphoma. The study involves an experimental treatment using the patient’s own immune cells (T cells) that have been genetically modified to help recognize and attack their cancer. Specifically, the study will evaluate a gene transfer product called rondecabtagene autoleucel (ronde-cel), which is known as a type of CAR T cell and targets 2 proteins on cancer cells, namely CD19 and CD20. Researchers will evaluate how well ronde-cel destroys cancer cells and determine whether ronde-cel destroys cancer cells the same as, or better than, other CAR T cell drugs that target only CD19 on cancer cells and are already approved by the U.S. Food and Drug Administration (FDA). Participants will be asked to undergo leukapheresis (a procedure to remove white blood cells from the blood), chemotherapy, and CAR T cell drug administration. They will be randomly assigned to receive either ronde-cel, a dual CD19/CD20 targeting CAR T, or an approved single CD19-targeting CAR T cell drug (axi-cel or liso-cel). Study procedures also include follow-up exams and blood collection.

Eligibility

Where can I participate?